A cellular model reflecting the phenotypic heterogeneity of mutant HRAS driven squamous cell carcinoma
暂无分享,去创建一个
Marcus Buschbeck | Roberto Malinverni | J. Martı́n-Caballero | E. Musulen | M. Fernández-Figueras | R. Malinverni | S. Goldie | M. Buschbeck | S. Forcales | Neus Cantariño | Neus Cantariño | Eva Musulén | Vanesa Valero | Julien Douet | M. Teresa Fernández‐Figueras | Isabel Granada | Stephen J. Goldie | Juan Martín‐Caballero | Sonia‐Vanina Forcales | I. Granada | J. Douet | Vanesa Valero
[1] P. Thompson,et al. The protein arginine deiminases: Structure, function, inhibition, and disease. , 2013, Biopolymers.
[2] G. Linette,et al. Histopathologic characteristics of therapy‐associated cutaneous neoplasms with vemurafenib, a selective BRAF kinase inhibitor, used in the treatment of melanoma , 2014, Journal of cutaneous pathology.
[3] S. Frankel,et al. Non-melanoma Skin Cancer , 2021, Surgical Oncology Manual.
[4] M. Feltkamp,et al. Human Beta‐papillomavirus infection and keratinocyte carcinomas , 2015, The Journal of pathology.
[5] J. Reis-Filho,et al. Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF , 2010, Cell.
[6] F. Watt,et al. FRMD4A upregulation in human squamous cell carcinoma promotes tumor growth and metastasis and is associated with poor prognosis. , 2012, Cancer research.
[7] J. L. Smith,et al. Incidence Estimate of Nonmelanoma Skin Cancer in the United States, 2006 , 2011 .
[8] D. Schadendorf,et al. RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] M. Belvin,et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth , 2010, Nature.
[10] A. Hauschild,et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. , 2011, The New England journal of medicine.
[11] J. Martı́n-Caballero,et al. MacroH2A1 Regulates the Balance between Self-Renewal and Differentiation Commitment in Embryonic and Adult Stem Cells , 2012, Molecular and Cellular Biology.
[12] Yu Shyr,et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. , 2012, The New England journal of medicine.
[13] W. V. van Venrooij,et al. Recombinant human monoclonal autoantibodies specific for citrulline-containing peptides from phage display libraries derived from patients with rheumatoid arthritis. , 2003, The Journal of rheumatology.
[14] Qi-En Wang,et al. DKK3 is a potential tumor suppressor gene in papillary thyroid carcinoma. , 2013, Endocrine-related cancer.
[15] M. Tormo,et al. Prognostic significance of complex karyotype and monosomal karyotype in adult patients with acute lymphoblastic leukemia treated with risk‐adapted protocols , 2014, Cancer.
[16] A. Ariza,et al. Primary Renal Cell Carcinoma in a Transplanted Kidney: Genetic Evidence of Recipient Origin , 2009, Transplantation.
[17] K. Flaherty,et al. Inhibition of mutated, activated BRAF in metastatic melanoma. , 2010, The New England journal of medicine.
[18] J. Martı́n-Caballero,et al. E-box-independent regulation of transcription and differentiation by MYC , 2011, Nature Cell Biology.
[19] Y. Fukui. Mechanisms behind signet ring cell carcinoma formation. , 2014, Biochemical and biophysical research communications.
[20] Fiona M. Watt,et al. Epithelial stem cells, wound healing and cancer , 2012, Nature Reviews Cancer.
[21] P. Khavari,et al. CDK4 coexpression with Ras generates malignant human epidermal tumorigenesis , 2002, Nature Medicine.
[22] O. Griffith,et al. Identification of PADI2 as a potential breast cancer biomarker and therapeutic target , 2012, BMC Cancer.
[23] S. Feldman,et al. Incidence Estimate of Nonmelanoma Skin Cancer (Keratinocyte Carcinomas) in the U.S. Population, 2012. , 2015, JAMA dermatology.
[24] Suzanne Schubbert,et al. Hyperactive Ras in developmental disorders and cancer , 2007, Nature Reviews Cancer.
[25] M. Simon,et al. Peptidylarginine deiminase isoforms 1-3 are expressed in the epidermis and involved in the deimination of K1 and filaggrin. , 2005, The Journal of investigative dermatology.
[26] D. Hanahan,et al. Hallmarks of Cancer: The Next Generation , 2011, Cell.
[27] A. McCullough. RAS Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors , 2013 .
[28] C. Creppe,et al. A Cbx8-Containing Polycomb Complex Facilitates the Transition to Gene Activation during ES Cell Differentiation , 2014, PLoS genetics.
[29] A. Levine,et al. Surfing the p53 network , 2000, Nature.
[30] T. Jacks,et al. Sunburn and p53 in the onset of skin cancer , 1994, Nature.
[31] Jeung-Hoon Lee,et al. Expression and Functional Role of Sox9 in Human Epidermal Keratinocytes , 2013, PloS one.
[32] D. Brash. Roles of the transcription factor p53 in keratinocyte carcinomas , 2006, The British journal of dermatology.
[33] J. Levine,et al. Surfing the p53 network , 2000, Nature.
[34] P. Boukamp. Non-melanoma skin cancer: what drives tumor development and progression? , 2005, Carcinogenesis.
[35] S. Horibata,et al. PAD2 overexpression in transgenic mice promotes spontaneous skin neoplasia. , 2014, Cancer research.
[36] G. Kristiansen,et al. Wnt signalling in human breast cancer: expression of the putative Wnt inhibitor Dickkopf-3 (DKK3) is frequently suppressed by promoter hypermethylation in mammary tumours , 2008, Breast Cancer Research.
[37] V. Petronic-Rosic,et al. Update on immunohistochemical methods relevant to dermatopathology. , 2009, Archives of pathology & laboratory medicine.
[38] S. Alowami,et al. Signet ring squamous cell carcinoma–the forgotten variant: case report and review of the literature , 2011, Journal of cutaneous pathology.
[39] Robert A. Weinberg,et al. Creation of human tumour cells with defined genetic elements , 1999, Nature.
[40] Remco Loos,et al. Citrullination regulates pluripotency and histone H1 binding to chromatin , 2014, Nature.
[41] J. Shay,et al. H-Ras Expression in Immortalized Keratinocytes Produces an Invasive Epithelium in Cultured Skin Equivalents , 2009, PloS one.
[42] Chao Zhang,et al. RAF inhibitors transactivate RAF dimers and ERK signaling in cells with wild-type BRAF , 2010, Nature.